0000950170-23-026821.txt : 20230607 0000950170-23-026821.hdr.sgml : 20230607 20230607162637 ACCESSION NUMBER: 0000950170-23-026821 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230607 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230607 DATE AS OF CHANGE: 20230607 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DICE Therapeutics, Inc. CENTRAL INDEX KEY: 0001645569 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472286244 STATE OF INCORPORATION: DE FISCAL YEAR END: 1230 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40794 FILM NUMBER: 23999320 BUSINESS ADDRESS: STREET 1: 400 EAST JAMIE COURT STREET 2: SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-566-1402 MAIL ADDRESS: STREET 1: 400 EAST JAMIE COURT STREET 2: SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: DiCE MOLECULES HOLDINGS, LLC DATE OF NAME CHANGE: 20180725 FORMER COMPANY: FORMER CONFORMED NAME: DiCE Molecules Holdings, LLC DATE OF NAME CHANGE: 20150617 8-K 1 dice-20230607.htm 8-K 8-K
0001645569--12-30false00016455692023-06-072023-06-07

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 07, 2023

 

 

DICE THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40794

47-2286244

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

400 East Jamie Court, Suite 300

 

South San Francisco, California

 

94080

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 650 566-1420

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 Par Value Per Share

 

DICE

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

As further described below in Item 5.07 of this Current Report on Form 8-K, on June 7, 2023, at the Annual Meeting of Stockholders (the “Annual Meeting”) of DICE Therapeutics, Inc. (the “Company”), the Company’s stockholders approved an amended and restated certificate of incorporation (the “Amended and Restated Certificate of Incorporation”) to permit the exculpation of the Company’s officers from liability in certain circumstances. On June 7, 2023, the Company filed with the Secretary of State of the State of Delaware the Amended and Restated Certificate of Incorporation.

A description of the Amended and Restated Certificate of Incorporation is set forth in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2023 in the section entitled “Proposal No. 3 – Approval of an Amended and Restated Certificate of Incorporation to Permit the Exculpation of Officers,” which description is incorporated herein by reference. The description is qualified in its entirety by reference to the full text of the Amended and Restated Certificate of Incorporation, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The final voting results for the Annual Meeting are as follows:

 

Proposal No. 1 – Election of Class II Directors

The Company’s stockholders elected the two Class II director nominees to the Company’s Board of Directors for a term of three years expiring with respect to each director at the annual meeting of stockholders to be held in 2026 and until such director’s successor is duly elected and qualified or until such director’s earlier resignation or removal, with the votes cast as follows:

 

Nominee

Votes For

Votes Withheld

Broker Non-Votes

Jim Scopa

32,540,055

9,054,159

3,655,517

Jake Simson, Ph.D.

32,596,683

8,997,531

3,655,517

 

Proposal No. 2 – Ratification of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023, with the votes cast as follows:

 

Votes For

Votes Against

Votes Withheld

Broker Non-Votes

45,245,715

3,113

903

—

 

Proposal No. 3 – Approval of an Amended and Restated Certificate of Incorporation to permit the Exculpation of Officers

The Company’s stockholders approved the Amended and Restated Certificate of Incorporation to permit the exculpation of officers in certain circumstances, with the votes cast as follows:

 

Votes For

Votes Against

Votes Withheld

Broker Non-Votes

40,311,115

1,282,156

943

3,655,517

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

 

 

3.1

Amended and Restated Certificate of Incorporation.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

DICE THERAPEUTICS, INC.

 

 

 

 

Date:

June 7, 2023

By:

/s/ Scott Robertson

 

 

 

Scott Robertson
Chief Business and Financial Officer

 

 EX-3.1 2 dice-ex3_1.htm EX-3.1 EX-3.1

 

Exhibt 3.1

 

DICE THERAPEUTICS, INC.

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

DICE Therapeutics, Inc., a Delaware corporation, hereby certifies as follows:

1.
The name of this corporation is “DICE Therapeutics, Inc.” The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was September 14, 2021 under the name DICE Therapeutics, Inc.
2.
The Amended and Restated Certificate of Incorporation of this corporation attached hereto as Exhibit A, which is incorporated herein by this reference, and which restates, integrates and further amends the provisions of the Certificate of Incorporation of this corporation as previously amended and/or restated, has been duly adopted by this corporation’s Board of Directors and by the stockholders in accordance with Sections 242 and 245 of the General Corporation Law of the State of Delaware, with the approval of this corporation’s stockholders having been given by written consent without a meeting in accordance with Section 228 of the General Corporation Law of the State of Delaware.

IN WITNESS WHEREOF, this corporation has caused this Amended and Restated Certificate of Incorporation to be signed by its duly authorized officer and the foregoing facts stated herein are true and correct.

 

Dated: June 7, 2023

 

DICE THERAPEUTICS, INC.

 

 

 

By:

/s/ Kevin Judice

 

 

Name:

Title:

J. Kevin Judice
Chief Executive Officer

 

 

 

 

DICE THERAPEUTICS, INC.

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

ARTICLE I: NAME

The name of the corporation is DICE Therapeutics, Inc. (the “Corporation”).

ARTICLE II: AGENT FOR SERVICE OF PROCESS

The address of the registered office of this Corporation in the State of Delaware is 1209 Orange Street, City of Wilmington, County of New Castle, 19801. The name of the registered agent of this Corporation in the State of Delaware at such address is The Corporation Trust Company.

ARTICLE III: PURPOSE

The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware (the “General Corporation Law”).

ARTICLE IV: AUTHORIZED STOCK

1.
Total Authorized. The total number of shares of all classes of stock that the Corporation has authority to issue is 510,000,000 shares, consisting of two classes: 500,000,000 shares of Common Stock, $0.0001 par value per share (“Common Stock”), and 10,000,000 shares of Preferred Stock, $0.0001 par value per share (“Preferred Stock”).
2.
Designation of Additional Series.

2.1 The Board of Directors of the Corporation (the “Board”) is authorized, subject to any limitations prescribed by the law of the State of Delaware, to provide for the issuance of the shares of Preferred Stock in one or more series, and, by filing a Certificate of Designation pursuant to the applicable law of the State of Delaware (“Certificate of Designation”), to establish from time to time the number of shares to be included in each such series, to fix the designation, vesting, powers (including voting powers), preferences and relative, participating, optional or other special rights, if any, of the shares of each such series and any qualifications, limitations or restrictions thereof, and, except where otherwise provided in the applicable Certificate of Designation, to thereafter increase (but not above the total number of authorized shares of the Preferred Stock) or decrease (but not below the number of shares of such series then outstanding) the number of shares of any such series. The number of authorized shares of Preferred Stock may also be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of two-thirds of the voting power of all then-outstanding shares of capital stock of the Corporation entitled to vote thereon, voting together as a single class, without a separate vote of the holders of the Preferred Stock, irrespective of the provisions of Section 242(b)(2) of the General Corporation Law, unless a separate vote of the holders of one or more series is required pursuant to the terms of any Certificate of Designation; provided, however, that if two-thirds of the Whole Board (as defined below) has approved such increase or decrease of the number of authorized shares of Preferred Stock, then only the affirmative vote of the holders of a majority of the voting power of all then-outstanding shares of the capital stock of the Corporation entitled to vote thereon, voting together as a single class, without a separate vote of the holders of the Preferred Stock, irrespective of the provisions of Section 242(b)(2) of the General Corporation Law, unless a separate vote of the holders of one or more series is required pursuant to the terms of any Certificate of Designation, shall be required to effect such increase or decrease. For purposes of this Amended and Restated Certificate of Incorporation (as the same may be amended and/or restated from time to time, including pursuant to the terms of any Certificate of Designation designating a series of Preferred Stock, this “Certificate of Incorporation”), the term “Whole Board” shall mean the total number of authorized directors whether or not there exist any vacancies in previously authorized directorships.

2.2 Except as otherwise expressly provided in any Certificate of Designation designating any series of Preferred Stock pursuant to the foregoing provisions of this Article IV, any new series of Preferred Stock may be designated, fixed and determined as provided herein by the Board without approval of the holders of Common Stock or the holders of Preferred Stock, or any series thereof, and any such new series may have powers, preferences and rights, including, without limitation, voting powers, dividend rights, liquidation rights, redemption rights and conversion rights, senior to, junior to or pari passu with the rights of the Common Stock, any series of Preferred Stock or any future class or series of capital stock of the Corporation.

 

2.3 Each outstanding share of Common Stock shall entitle the holder thereof to one vote on each matter properly submitted to the stockholders of the Corporation for their vote; provided,that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation (including any Certificate of Designation relating to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon pursuant to this Certificate of Incorporation (including any Certificate of Designation relating to any series of Preferred Stock).

ARTICLE V: AMENDMENT OF BYLAWS

The Board shall have the power to adopt, amend or repeal the Bylaws of the Corporation (as the same may be amended and/or restated from time to time, the “Bylaws”). Any adoption, amendment or repeal of the Bylaws by the Board shall require the approval of a majority of the Whole Board. The stockholders shall also have power to adopt, amend or repeal the Bylaws; provided,that, notwithstanding any other provision of this Certificate of Incorporation or any provision of law that might otherwise permit a lesser or no vote, but in addition to any vote of the holders of any class or series of stock of the Corporation required by applicable law or by this Certificate of Incorporation (including any Preferred Stock issued pursuant to a Certificate of Designation), the affirmative vote of the holders of at least two-thirds of the voting power of all then-outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required for the stockholders to adopt, amend or repeal any provision of the Bylaws; provided, further, that, in the case of any proposed adoption, amendment or repeal of any provisions of the Bylaws that is approved by the Board and submitted to the stockholders for adoption thereby, if two-thirds of the Whole Board has approved such adoption, amendment or repeal of any provisions of the Bylaws, then only the affirmative vote of the holders of a majority of the voting power of all then-outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class (in addition to any vote of the holders of any class or series of stock of the Corporation required by applicable law or by this Certificate of Incorporation (including any Preferred Stock issued pursuant to a Certificate of Designation), shall be required to adopt, amend or repeal any provision of the Bylaws.

ARTICLE VI: MATTERS RELATING TO THE BOARD OF DIRECTORS

1.
Director Powers. Except as otherwise provided by the General Corporation Law, the Bylaws of the Corporation or this Certificate of Incorporation, the business and affairs of the Corporation shall be managed by or under the direction of the Board.
2.
Number of Directors. Subject to the special rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, the total number of directors constituting the Whole Board shall be fixed from time to time exclusively by resolution adopted by a majority of the Whole Board.
3.
Classified Board. Subject to the special rights of the holders of one or more series of Preferred Stock to elect additional directors under specified circumstances, the directors shall be divided, with respect to the time for which they severally hold office, into three classes designated as Class I, Class II and Class III, respectively (the “Classified Board”). The Board may assign members of the Board already in office to the Classified Board, which assignments shall become effective at the same time that the Classified Board becomes effective. Directors shall be assigned to each class in accordance with a resolution or resolutions adopted by the Board. The number of directors in each class shall be divided as nearly equal as is practicable. The initial term of office of the Class I directors shall expire at the Corporation’s first annual meeting of stockholders following the closing of the Corporation’s initial public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, relating to the offer and sale of Common Stock to the public (the “Initial Public Offering”), the initial term of office of the Class II directors shall expire at the Corporation’s second annual meeting of stockholders following the closing of the Initial Public Offering and the initial term of office of the Class III directors shall expire at the Corporation’s third annual meeting of stockholders following the closing of the Initial Public Offering. At each annual meeting of stockholders following the closing of the Initial Public Offering, directors elected to succeed those directors of the class whose terms then expire shall be elected for a term of office expiring at the third succeeding annual meeting of stockholders after their election.
4.
Term and Removal. Each director shall hold office until the annual meeting at which such director’s term expires and until such director’s successor is duly elected and qualified, or until such director’s earlier death, resignation, disqualification or removal. Any director may resign at any time by delivering a resignation in writing or by electronic transmission to the Corporation at its principal office or to the Chairperson of the Board, the Chief Executive Officer, or the Secretary. Subject to the special rights of the holders of any series of Preferred Stock, no director may be removed from the Board except for cause and only by the affirmative vote of the holders of at least two-thirds of the voting power of the

 

then-outstanding shares of capital stock of the Corporation entitled to vote thereon, voting together as a single class. In the event of any increase or decrease in the authorized number of directors, (a) each director then serving as such shall nevertheless continue as a director of the class of which he or she is a member and (b) the newly created or eliminated directorships resulting from such increase or decrease shall be apportioned by the Board among the classes of directors so as to make all classes as nearly equal in number as is practicable, provided that no decrease in the number of directors constituting the Board shall shorten the term of any director.
5.
Board Vacancies and Newly Created Directorships. Subject to the special rights of the holders of any series of Preferred Stock, any vacancy occurring in the Board for any cause, and any newly created directorship resulting from any increase in the authorized number of directors, shall, unless (a) the Board determines by resolution that any such vacancies or newly created directorships shall be filled by the stockholders or (b) as otherwise provided by law, be filled only by the affirmative vote of a majority of the directors then in office, even if less than a quorum, or by a sole remaining director, and shall not be filled by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for a term expiring at the annual meeting of stockholders at which the term of office of the class to which the director has been assigned expires and until such director’s successor shall have been duly elected and qualified, or until such director’s earlier death, resignation, disqualification or removal.
6.
Vote by Ballot. Election of directors need not be by written ballot unless the Bylaws shall so provide.

ARTICLE VII:LIMITATION OF LIABILITY

1.
Limitation of Liability. To the fullest extent permitted by law, neither a director of the Corporation nor an officer of the corporation shall be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, as applicable. Without limiting the effect of the preceding sentence, if the General Corporation Law is hereafter amended to authorize the further elimination or limitation of the liability of a director or officer, then the liability of a director or officer of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law, as so amended.
2.
Change in Rights. Neither any amendment nor repeal of this Article VII, nor the adoption of any provision of this Amended and Restated Certificate of Incorporation inconsistent with this Article VII, shall eliminate, reduce or otherwise adversely affect any limitation on the personal liability of a director or officer of the Corporation existing at the time of such amendment, repeal or adoption of such an inconsistent provision.

ARTICLE VIII: MATTERS RELATING TO STOCKHOLDERS

1.
No Action by Written Consent of Stockholders. Subject to the rights of any series of Preferred Stock then outstanding, no action shall be taken by the stockholders of the Corporation except at a duly called annual or special meeting of stockholders and no action shall be taken by the stockholders of the Corporation by written consent in lieu of a meeting.
2.
Special Meeting of Stockholders. Special meetings of the stockholders of the Corporation may be called only by the Chairperson of the Board, the Chief Executive Officer, the Lead Independent Director (as defined in the Bylaws), the President, or the Board acting pursuant to a resolution adopted by a majority of the Whole Board and may not be called by the stockholders or any other person or persons.
3.
Advance Notice of Stockholder Nominations and Business Transacted at Special Meetings. Advance notice of stockholder nominations for the election of directors of the Corporation and of business to be brought by stockholders before any meeting of stockholders of the Corporation shall be given in the manner provided in the Bylaws. Business transacted at special meetings of stockholders shall be limited to the purpose or purposes stated in the notice of meeting.

ARTICLE IX: CHOICE OF FORUM

Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for: (a) any derivative action or proceeding brought on behalf of the Corporation; (b) any action asserting a claim of breach of a fiduciary duty owed by, or other wrongdoing by, any director, officer, stockholder, employee or agent of the Corporation to the Corporation or the Corporation’s stockholders; (c) any action asserting a claim against the Corporation or any director, officer, stockholder, employee or agent of the Corporation arising pursuant to any provision of the General Corporation Law, this Certificate of Incorporation or the Bylaws or as to which the General Corporation Law confers jurisdiction on the Court of Chancery of the State of Delaware; (d) any action to interpret, apply, enforce or determine the validity of this Certificate of Incorporation or the

 

Bylaws; or (e) any action asserting a claim against the Corporation or any director, officer, stockholder, employee or agent of the Corporation governed by the internal affairs doctrine, provided that, for the avoidance of doubt, nothing in this Article IX shall preclude the filing of claims in the federal district courts of the United States of America under the Exchange Act, or any successor thereto. Any person or entity purchasing or otherwise acquiring or holding any interest in shares of capital stock of the Corporation shall be deemed to have notice of and to have consented to the provisions of this Article IX.

ARTICLE X: AMENDMENT OF CERTIFICATE OF INCORPORATION

If any provision of this Certificate of Incorporation shall be held to be invalid, illegal, or unenforceable, then such provision shall nonetheless be enforced to the maximum extent possible consistent with such holding and the remaining provisions of this Certificate of Incorporation (including, without limitation, all portions of any section of this Certificate of Incorporation containing any such provision held to be invalid, illegal, or unenforceable, which is not invalid, illegal, or unenforceable) shall remain in full force and effect.

The Corporation reserves the right to amend or repeal any provision contained in this Certificate of Incorporation in the manner prescribed by the laws of the State of Delaware and all rights conferred upon stockholders are granted subject to this reservation; provided, however, that, notwithstanding any other provision of this Certificate of Incorporation or any provision of law that might otherwise permit a lesser vote or no vote (but subject to the rights of any series of Preferred Stock set forth in any Certificate of Designation), but in addition to any vote of the holders of any class or series of the stock of the Corporation required by law or by this Certificate of Incorporation, the affirmative vote of the holders of at least two-thirds of the voting power of all then-outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend or repeal this Article X or Article V, Article VI, Article VII or Article VIII; provided,further, that if two-thirds of the Whole Board has approved such amendment or repeal of any provisions of this Certificate of Incorporation, then only the affirmative vote of the holders of a majority of the voting power of all then-outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class (in addition to any other vote of the holders of any class or series of stock of the Corporation required by law of by this Certificate of Incorporation or any Certificate of Designation), shall be required to amend or repeal such provisions of this Certificate of Incorporation.

* * * * * * * * * *

 EX-101.PRE 3 dice-20230607_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 4 dice-20230607.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 dice-20230607_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Current Fiscal Year End Date Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Securities Act File Number Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document And Entity Information
Jun. 07, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Current Fiscal Year End Date --12-30
Document Period End Date Jun. 07, 2023
Entity Registrant Name DICE THERAPEUTICS, INC.
Entity Central Index Key 0001645569
Entity Emerging Growth Company true
Securities Act File Number 001-40794
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 47-2286244
Entity Address, Address Line One 400 East Jamie Court, Suite 300
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code 650
Local Phone Number 566-1420
Entity Information, Former Legal or Registered Name N/A
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, $0.0001 Par Value Per Share
Trading Symbol DICE
Security Exchange Name NASDAQ
XML 7 dice-20230607_htm.xml IDEA: XBRL DOCUMENT 0001645569 2023-06-07 2023-06-07 0001645569 --12-30 false 8-K 2023-06-07 DICE THERAPEUTICS, INC. DE 001-40794 47-2286244 400 East Jamie Court, Suite 300 South San Francisco CA 94080 650 566-1420 N/A false false false false Common Stock, $0.0001 Par Value Per Share DICE NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 25 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports [dq-0540-CurrentFiscalYearEndDate-Registrant-Value] In submission type 8-K, CurrentFiscalYearEndDate value "--12-30", should match the Entity Registrant Fiscal Year End Date "12/31" on record within EDGAR. dice-20230607.htm 8 dice-20230607.htm dice-20230607.xsd dice-20230607_lab.xml dice-20230607_pre.xml dice-ex3_1.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "dice-20230607.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 25 }, "contextCount": 1, "dts": { "inline": { "local": [ "dice-20230607.htm" ] }, "labelLink": { "local": [ "dice-20230607_lab.xml" ] }, "presentationLink": { "local": [ "dice-20230607_pre.xml" ] }, "schema": { "local": [ "dice-20230607.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 0, "memberStandard": 0, "nsprefix": "dice", "nsuri": "http://www.dicetherapeutics.com/20230607", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "dice-20230607.htm", "contextRef": "C_10ffac16-1f82-485a-adce-88487ff222b6", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "dice-20230607.htm", "contextRef": "C_10ffac16-1f82-485a-adce-88487ff222b6", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.dicetherapeutics.com/20230607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0000950170-23-026821-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-026821-xbrl.zip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